VEA
ONC

Virtus ETF Advisers’s BeOne Medicines Ltd ONC Stock Holding History

Virtus ETF Advisers’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,940
Closed -$358K – 823
2024
Q4 		$358K Sell
1,940
-39
-2% -$7.97K 0.15% 194
2024
Q3 		$444K Hold
1,979
– – 0.21% 189
2024
Q2 		$282K Sell
1,979
-52
-3% -$8.01K 0.14% 234
2024
Q1 		$318K Buy
2,031
+292
+17% +$47K 0.17% 223
2023
Q4 		$314K Buy
1,739
+280
+19% +$50.7K 0.2% 218
2023
Q3 		$262K Sell
1,459
-192
-12% -$38K 0.16% 220
2023
Q2 		$294K Buy
1,651
+179
+12% +$41.2K 0.17% 209
2023
Q1 		$317K Buy
1,472
+26
+2% +$6.24K 0.17% 190
2022
Q4 		$318K Sell
1,446
-335
-19% -$61.4K 0.17% 242
2022
Q3 		$240K Buy
1,781
+23
+1% +$3.95K 0.1% 295
2022
Q2 		$285K Buy
1,758
+422
+32% +$65.9K 0.11% 269
2022
Q1 		$252K Hold
1,336
– – 0.11% 185
2021
Q4 		$362K Buy
1,336
+8
+0.6% +$2.7K 0.14% 180
2021
Q3 		$482K Sell
1,328
-120
-8% -$39.2K 0.21% 141
2021
Q2 		$497K Sell
1,448
-1,291
-47% -$428K 0.2% 153
2021
Q1 		$953K Buy
2,739
+70
+3% +$23.2K 0.4% 93
2020
Q4 		$690K Sell
2,669
-896
-25% -$247K 0.29% 95
2020
Q3 		$1.02M Buy
3,565
+300
+9% +$70.5K 0.54% 71
2020
Q2 		$615K Sell
3,265
-78
-2% -$12.7K 0.29% 111
2020
Q1 		$412K Sell
3,343
-282
-8% -$44.1K 0.17% 195
2019
Q4 		$601K Buy
3,625
+1,470
+68% +$244K 0.1% 188
2019
Q3 		$264K Sell
2,155
-120
-5% -$15.9K 0.05% 209
2019
Q2 		$282K Buy
2,275
+234
+11% +$29.7K 0.06% 245
2019
Q1 		$269K Sell
2,041
-209
-9% -$28.2K 0.57% 69
2018
Q4 		$316K Sell
2,250
-399
-15% -$52.9K 0.05% 95
2018
Q3 		$456K Sell
2,649
-1,938
-42% -$326K 0.05% 135
2018
Q2 		$705K Sell
4,587
-3,495
-43% -$623K 0.62% 99
2018
Q1 		$1.36M Buy
8,082
+4,349
+117% +$589K 1.18% 9
2017
Q4 		$365K Sell
3,733
-4,380
-54% -$401K 0.46% 73
2017
Q3 		$839K Buy
8,113
+560
+7% +$41.7K 0.11% 70
2017
Q2 		$340K Sell
7,553
-2,116
-22% -$83.4K 0.05% 91
2017
Q1 		$354K Buy
9,669
+927
+11% +$33.8K 0.06% 122
2016
Q4 		$265K Buy
8,742
+398
+5% +$12.5K 0.08% 126
2016
Q3 		$257K Hold
8,344
– – 0.12% 122
2016
Q2 		$249K Buy
+8,344
New +$245K 0.18% 90

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Virtus ETF Advisers's ONC Position: Q1 2025 in Review

Virtus ETF Advisers sold out of BeOne Medicines Ltd (ONC) in Q1 2025, closing a stake of 1,940 shares — an estimated $358K sold.

Virtus ETF Advisers first reported a position in ONC in Q2 2016 and held it in 35 quarters. The position peaked at $1.36M in Q1 2018. 267 funds tracked by Wall St. Rank hold ONC as of Q1 2025.

  • Virtus ETF Advisers reported no remaining BeOne Medicines Ltd position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,940 BeOne Medicines Ltd shares in Q1 2025, an estimated $358K.
  • Virtus ETF Advisers first reported a position in BeOne Medicines Ltd in Q2 2016 and held it in 35 quarters.
  • Virtus ETF Advisers's BeOne Medicines Ltd position peaked at $1.36M in Q1 2018.
  • 267 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.